Dear Colleagues and Friends,

After a successful start of the IUIS second Webinar Series: Immunology without Borders, IUIS is happy to announce the next live webinar on “Harnessing innate immunity in cancer therapy and beyond” with Eric Vivier on March 1!

IUIS collaborates with Frontiers & immunopaedia, on a series of biweekly, expert commentaries and scientific webinars. Keep an eye open for the upcoming announcements or check here to see the upcoming events!

Harnessing innate immunity in cancer therapy and beyond

Date: March 1, 2021
Time: 15:00 (CET)

Eric Vivier will talk about new therapies that promote anti-tumor immunity, which have been recently developed.
He will present innovative anti-tumor therapies based on the manipulation of the innate immune system. In addition, given the urgent need for effective treatments for pneumonia in patients with COVID-19, the elucidation of the immune responses that occur during the course of COVID-19 could lead to the repurposing of approved immunomodulatory drugs and candidate drugs that have already been tested in clinical trials.
Along this line, he will present the results indicating the association of COVID-19 inflammation with activation of the C5a–C5aR1 axis.

Eric Vivier is Professor of Immunology at Aix-Marseille University and at the Public Hospital of Marseille (AP-HM), in addition to being Scientific Director of Innate Pharma. His work focuses on innate immunity and in particular Natural killer and other innate lymphoid cells, at Ciml, at AP-HM and at Innate-Pharma.

The webinar will be moderated by Miriam Merad, M.D.; Ph.D. She is the Mount Sinai Endowed Professor in Cancer Immunology and the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York, as well as the Vice-President of IUIS.


On demand webinars

You can watch the first webinar of the Immunology without Borders Series, with Pamela Ohashi, about “Immunoregulation and the tumor microenvironment” on-demand at
You will find all webinars from the previous series on COVID-19 on this website as well.